



**BIOMARKERS IN
CLINICAL ONCOLOGY**

BIOMEDICA

EPITOPE-MAPPED ANTIBODIES

SERUM BASED CALIBRATORS & CONTROLS

VALIDATED ACCORDING TO ICH AND FDA GUIDELINES

Setting the **standard**
for **clinical** research.



DKK-1 • free sRANKL • OPG • Periostin • Semaphorin 4D

Dickkopf-1 (DKK-1) ELISA (BI-20413)

| | |
|-----------------|-----------------------------------|
| Method | Sandwich ELISA, HRP/TMB |
| Sample type | Serum, cell culture supernatants |
| Sample size | 20 µl / test, 12x8 tests |
| Standard range | 0 – 160 pmol/l |
| Detection limit | 1.7 pmol/l |
| Assay time | 3.5 h |
| Use | CE marked – for IVD use in the EU |
| References | 45 |

- Marker for bone metastasis and osteolytic bone lesions
- Potential prognostic marker and therapeutic target

Free soluble RANKL ELISA (BI-20462)

| | |
|-----------------|-----------------------------------|
| Method | Sandwich ELISA, HRP/TMB |
| Sample type | Serum, plasma (heparin) |
| Sample size | 150 µl / test, 12x8 tests |
| Standard range | 0 – 2 pmol/l |
| Detection limit | 0.01 pmol/l |
| Assay time | Overnight assay |
| Use | CE marked – for IVD use in the EU |
| References | 100+ |

- Dysregulated in primary bone cancers and cancers metastasizing to the bone
- Associated with tumor invasiveness

Osteoprotegerin (OPG) ELISA (BI-20403)

| | |
|-----------------|-----------------------------------|
| Method | Sandwich ELISA, HRP/TMB |
| Sample type | Serum, plasma |
| Sample size | 20 µl / test, 12x8 tests |
| Standard range | 0 – 20 pmol/l |
| Detection limit | 0.07 pmol/l |
| Assay time | 5.5 h |
| Use | CE marked – for IVD use in the EU |
| References | 96 |

- Therapeutic target

Periostin ELISA (BI-20433) **NEW**

| | |
|-----------------|---|
| Method | Sandwich ELISA, HRP/TMB |
| Sample type | Serum, plasma, urine, cell culture supernatants |
| Sample size | 10 µl / test, 12x8 tests |
| Standard range | 0 – 4000 pmol/l |
| Detection limit | 20 pmol/l |
| Assay time | 5.5 h |
| Use | Research use only |

- Increases cell survival and invasiveness
- Potential prognostic marker and therapeutic target

Soluble Semaphorin 4D ELISA (BI-20405) **NEW**

| | |
|-----------------|--------------------------|
| Method | Sandwich ELISA, HRP/TMB |
| Sample type | Plasma |
| Sample size | 10 µl / test, 12x8 tests |
| Standard range | 0 – 2000 pmol/l |
| Detection limit | 12 pmol/l |
| Assay time | 4.5 h |
| Use | Research use only |

- Pro-angiogenic
- Inducer of tumor cell invasiveness
- Potential therapeutic target

Total soluble Neuropilin-1 ELISA (BI-20409) **NEW**

| | |
|-----------------|--------------------------|
| Method | Sandwich ELISA, HRP/TMB |
| Sample type | Serum, plasma |
| Sample size | 10 µl / test, 12x8 tests |
| Standard range | 0 – 12 nmol/l |
| Detection limit | 0.09 nmol/l |
| Assay time | 4 h |
| Use | Research use only |

- Antagonist of VEGF-mediated angiogenesis
- Potential diagnostic marker in cervical cancer
- Potential therapeutic target

Neuropilin-1 • Sclerostin • Endostatin • Big Endothelin • FGF23

Sclerostin ELISA (BI-20492)

| | |
|-----------------|---|
| Method | Sandwich ELISA, HRP/TMB |
| Sample type | Serum, plasma (EDTA, heparin), urine, cell culture supernatants |
| Sample size | 20 µl / test, 12x8 tests |
| Standard range | 0 – 240 pmol/l |
| Detection limit | 3.2 pmol/l |
| Assay time | Overnight assay |
| Use | Research use only |
| References | 100+ |

- Dysregulated in cancers targeting the bone
- Marker for cancer-induced osteolytic bone loss
- Therapeutic target

Bioactive Sclerostin ELISA (BI-20472) **NEW**

| | |
|-----------------|---|
| Method | Sandwich ELISA, HRP/TMB |
| Sample type | Serum, plasma (EDTA, citrate), urine, cell culture supernatants |
| Sample size | 20 µl / test, 12x8 tests |
| Standard range | 0 – 320 pmol/l |
| Detection limit | 1.9 pmol/l |
| Assay time | 3.5 h |
| Use | Research use only |

Endostatin ELISA (BI-20742) **NEW**

| | |
|-----------------|-----------------------------|
| Method | Sandwich ELISA, HRP/TMB |
| Sample type | Serum, plasma, urine |
| Sample size | 10-20 µl / test, 12x8 tests |
| Standard range | 0 – 800 pmol/l |
| Detection limit | 4 pmol/l |
| Assay time | 4.5 h |
| Use | Research use only |

- Anti-angiogenic
- Potential prognostic marker, especially in combination with VEGF
- Therapeutic target

Endostatin mouse/rat ELISA (BI-20742MR) **NEW**

| | |
|-----------------|-------------------------|
| Method | Sandwich ELISA, HRP/TMB |
| Sample type | Serum, plasma |
| Sample size | 5 µl / test, 12x8 tests |
| Standard range | 0 – 32 nmol/l |
| Detection limit | 0.24 nmol/l |
| Assay time | 2.5 h |
| Use | Research use only |

Big Endothelin ELISA (BI-20082H)

| | |
|-----------------|-----------------------------------|
| Method | Sandwich ELISA, HRP/TMB |
| Sample type | Serum, plasma |
| Sample size | 50 µl / test, 12x8 tests |
| Standard range | 0 – 3 pmol/l |
| Detection limit | 0.02 pmol/l |
| Assay time | 5.5 h |
| Use | CE marked – for IVD use in the EU |
| References | 42 |

- Promotes proliferation, survival, neovascularization, and invasiveness
- Indicates poor prognosis

FGF23 (C-terminal) ELISA (BI-20702)

| | |
|-----------------|-----------------------------------|
| Method | Sandwich ELISA, HRP/TMB |
| Sample type | Serum, plasma |
| Sample size | 50 µl / test, 12x8 tests |
| Standard range | 0 – 20 pmol/l |
| Detection limit | 0.08 pmol/l |
| Assay time | Overnight assay |
| Use | CE marked – for IVD use in the EU |
| References | 10 |

- Marker for tumor-induced osteomalacia

Setting the **standard** for **clinical** research.



www.bmgrp.com



Divischgasse 4 · 1210 Vienna · Austria
T +43 1 291 07 45 · F +43 1 291 07 85
info@bmgrp.com · www.bmgrp.com

